Synergism of components as the main approach to creation of a probiotic complex

Development of probiotic products containing several strains: Bifidumbacterium lactis BI-04, Lactobacillus acidophilus La-14 and Lactobacillus rhamnosus Lr-32, is an upcoming trend, as it builds capacity of preventive treatment. According to the results of in vitro experimental studies, the strains of Lactobacillus acidophilus La-14, L. rhamnosus Lr-32, Bifidumbacterium lactis BI-04 are resistant to low pH conditions and survive in the concentrations of bile salts in the small intestine. Demonstrate high adhesion to the human epithelial cell lines - Caco-2 and HT-29. In vitro experiments have shown the inhibitory effect of strains L. acidophilus La-14, L. rhamnosus Lr-32 on the following pathogens: Salmonella typhimurium, Staphylococcus aureus, Escherichia coli, Listeria monocytogenes. The probiotic strains with in vitro and in vivo confirmed effects combined a prebiotic and B vitamins is considered a rational combination. Additional favourable conditions in the form of nutrient medium (prebiotic), sufficient energy supply (coenzyme vitamins) contribute towards the increase of colonization potential. Inulin and B vitamins have their own activity, which is synergistic with the probiotic microorganism activity. Vitamin B12 has a porphyrin-like or corrine ring in its structure, which is linked to the cobalt atom by four coordination bonds and is representative of corrinoids group. Microorganisms inhabiting the GI tract use exogenously produced cobalamin corrinoids as cofactors. It is appropriate to add the use of probiotics with additional exogenous intake of vitamin B12, as microbial communities of the human gut are likely competitors in the consumption of cobalamin. The rational selection of components contributes to the maximum implementation of potential preventive effects of probiotic microorganisms.

1. Nikonov E.L., Popova E.L. (ed.). Microbiota. Moscow: Media Sfera; 2019. 255 с. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=38244535.

2. Venugopalan V., Shriner K.A., Wong-Beringer A. Regulatory Oversight and Safety of Probiotic Use. Emerging Infectious Diseases. 2010;16(11):1661-1665. doi: 10.3201/eid1611.100574.

3. Binns N. Probiotics, Prebiotics and the gut microbiota. Brussels; 2013. 32 p. Available at: https://ilsi.org/europe/wp-content/uploads/sites/3/2016/05/Prebiotics-Probiotics.pdf.

4. Andoh A. Physiological Role of Gut Microbiota for Maintaining Human Health. Digestion. 2016;93(3):176-181. doi: 10,1159/000444066.

5. Potapov V.A. Probiotics in gynecology: fashion or aware of the need (market watch). Z turbotoyu pro zhinku = With the care of a woman. 2015;(1):10-15. (In Russ.) Available at: https://organosyn.com.ua/down-loads/0000/0623/article_8_5.pdf.

6. Gomaa A., Verghese M., Herring J. Inhibition of Antimicrobial Resistant Salmonella Heidelberg by a Synbiotic Combination of Prebiotics and Probiotics in an in Vitro Model (P20-011-19). Curr Dev Nutr. 2019;3(1):nzz040. doi: 10.1093/cdn/nzz040.P20-011-19.

7. Lyra A., Hillila M., Huttunen T., Mannikko S., Taalikka M., Tennilaet J. et al. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J Gastroenterol. 2016;22(48):10631-10642. doi: 10.3748/wjg.v22.i48.10631.

8. Ouwehand A.C., DongLian C., Weijian X., Stewart M., Ni J., Stewart T., Miller L.E. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458-463. doi: 10.1016/j.vaccine.2013.11.053.

9. Forssten S., Evans M., Wilson D., Ouwehand A.C. Influence of a probiotic mixture on antibiotic induced microbiota disturbances. World J Gastroenterol. 2014;20(33):11878-11885. doi: 10.3748/wjg.v20.i33.11878.

10. Guarner F., Khan A.G., Garisch J., Fedorak R., Gangl A., Garisch J. et al. Probiotics and prebiotics. World Gastroenterology Organisation Global Guidelines. 2017. 37 p. Available at: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2017.pdf.

11. Turroni S., Vitali B., Bendazzoli C., Candela M., Gotti R., Federici F., Pirovano F., Brigid P. Oxalate consumption by lactobacilli: evaluation of oxalyl-CoA decarboxylase and formyl-CoA transferase activity in Lactobacillus acidophilus. J Appl Microbiol. 2007;103(5):1600-1609. doi: 10.1111/j.1365-2672.2007.03388.x.

12. Luo X.Y., Lun Y.Z., Gao W., Hu H.B., Wang Q., Liu Y., Yin J.S., Jiang SJ. Effects of spent culture supernatant of Lactobacillus acidophilus on intestinal flora in mice with antibiotic- associated diarrhoea. Shijie Huaren Xiaohua Zazhi. 2006;14(19):1870-1873. doi: 10.11569/wcjd.v14.i19.1870.

13. Cani P.D. Human gut microbiome: hopes, threats and promises. Gut. 2018;67(9):1716-1725. doi: 10.1136/gutjnl-2018-316723.

14. Khramtsov A.G., Ryabtseva S.A., Budkevich R.O., Akhmedova V.R., Rodnaya A.B., Marugina E.V. Prebiotics as functional food ingredients: terminology, choice and comparative evaluation criteria, classification. Voprosy pitaniya = Problems of Nutrition. 2018;87(1):5-17. (In Russ.) doi: 10.24411/0042-8833-2018-10001.

15. Pineiro M.. Asp N.G., Reid G., Macfarlane S.. Morelli L., Brunser O., Tuohy K. FAO technical meeting on prebiotics. J Clin Gastroenterol. 2008;42(3; 2):156-159. doi: 10.1097/MCG.0b013e31817f184e.

16. Roberfroid M. Prebiotics: the concept revisited. J Nutr. 2007;137(3):830-837. doi: 10.1093/jn/137.3.830S.

17. Butorova L.I. New opportunities for the prevention and treatment of chronic constipation with complex prebiotic drugs: choice of optimal combination. Gastroehnterologiia Sankt-Peterburga = Gastroenterology of St. Petersburg. 2012;(4):2-10. (In Russ.) Available at: http://gastroforum.ru/wp-content/uploads/2013/06/GSP_4_2012_P1-26_2-10.pdf.

18. Guess N.D., Dornhorst A., Oliver N., Bell J.D., Thomas E.L., Frost G.S. A randomized controlled trial: the effect of inulin on weight management and ectopic fat in subjects with prediabetes. Nutr Metab (Lond). 2015;12:36. doi: 10.1186/s12986-015-0033-2.

19. Kopylova D.V., Koshelev PI. Opportunities of butyric acid and inulin use in the early restoration period after kholetsistektomii. Lechashchiy vrach = Attending Doctor. 2013(2):121-125. (In Russ.) Available at: https://www. lvrach.ru/2013/02/15435641/.

20. Degnan PH., Taga M.E., Goodman A.L. Vitamin B12 as a Modulator of Gut Microbial Ecology. Cell Metabolism. 2014;20(5):769-778. doi: 10.1016/j.cmet.2014.10.002.

21. Keller S., Ruetz M., Kunze C., Krautler B., Diekert G., Schubert T. Exogenous 5,6-dimethylbenzimidazole caused production of a nonfunctional tetrachloroethene reductive dehalogenase in Sulfurospirillum multivorans. Environ Microbiol. 2014;16(11):3361-3369. doi: 10.1111/1462-2920.12268.

22. Nielsen MJ., Rasmussen M.R., Andersen C.B., Nexo E., Moestrup S.K. Vitamin B12 transport from food to the body's cells-a sophisticated, multistep pathway. Nature Rev Gastroenterol Hepatol. 2012;(9):345-354. doi: 10.1038/nrgastro.2012.76.

23. Men Y., Seth E.C., Yi S., Crofts T.S., Allen R.H., Taga M.E., Alvarez-Cohen L. Identification of specific corrinoids reveals corrinoid modification in dechlorinating microbial communities. Environ Microbiol. 2015;17(12):4873-4884. doi: 10.1111/1462-2920.12500.

24. Degnan PH., Barry N.A., Mok K.C., Taga M.E., Goodman A.L. Human gut microbes use multiple transporters to distinguish vitamin B12 analogs and compete in the gut. Cell Host Microbe. 2014;15(1):47-57. doi: 10.1016/j.chom.2013.12.007.

25. Shikh E.V., Makhova A.A. Vitamins in clinical practice: a scientific and practical edition. Moscow: Prakticheskaya meditsina; 2014. 367 p. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=25878355.

26. Gromov O.A., Torshin I.Yu., Gusev E.I. Synergistic neuroprotective effects of thiamine, pyridoxine and cyanocobalamin on the level of human pro-teome. Farmakokinetika i farmakodinamika = Pharmacokinetics and Pharmacodynamics. 2017;(1):40-51. (In Russ.) Available at: https://www.pharmacokinetica.ru/jour/article/view/7/7.